Castellan Group Raises Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Castellan Group lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 116,470 shares of the biopharmaceutical company’s stock after purchasing an additional 2,672 shares during the quarter. Halozyme Therapeutics accounts for about 2.4% of Castellan Group’s investment portfolio, making the stock its 17th biggest holding. Castellan Group owned 0.09% of Halozyme Therapeutics worth $5,568,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HALO. Congress Asset Management Co. boosted its holdings in Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Halozyme Therapeutics by 698.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock valued at $13,756,000 after buying an additional 251,711 shares during the period. Boston Trust Walden Corp boosted its stake in shares of Halozyme Therapeutics by 54.0% in the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock worth $39,073,000 after buying an additional 239,321 shares during the last quarter. South Street Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the third quarter worth $9,812,000. Finally, Hantz Financial Services Inc. purchased a new stake in Halozyme Therapeutics during the third quarter valued at $9,260,000. 97.79% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Trading Up 1.4 %

Shares of HALO stock opened at $58.11 on Thursday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The stock has a fifty day simple moving average of $52.09 and a two-hundred day simple moving average of $54.45. The firm has a market capitalization of $7.39 billion, a PE ratio of 19.24, a PEG ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 52-week low of $34.36 and a 52-week high of $65.53.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.